Thoughtworks Holding's low P/S ratio is likely due to poor revenue performance and expectations of this trend continuing. The company's inferior revenue forecasts compared to the industry may contribute to the low P/S ratio, suggesting the share price may not rise significantly soon.
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks. Here are some top stocks in the sector climbing on drug trial and earnings news: $Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap. $Ligand Pharmaceuticals (LGND.US)$gained 23%...
Thoughtworks Holding's downward trend in ROCE and the continued usage of the same amount of capital signify a potentially mature business showing signs of decline. Unless there's a shift in these metrics, it might be wise to consider investing elsewhere.
Insiders' purchase of shares above current prices signifies optimism for the stock's value and an alignment with shareholder interests. Despite no insider transactions in the last three months, Thoughtworks Holding insiders seem undeterred about the company's future.
Introduction The Digital IT Services group is expected to see a downside risk to its estimates, given weak demand for project-based services and possible delays in bookings ramp. Although snap-back potential to pre-pandemic growth rates is seen at some point next year, there is still caution in the group until stability in estimates is observed. Revision risk is possible, and negative revision trends have be...
ソートワークス・ホールディングに関するコメント
コラムBiotechnology Stocks Climbing on Earnings and Test Results: What to Watch
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Daily alerts recap 🔥 ALL STARS 🌟 45%+
コラムUS Top Gap Ups and Downs on 8/8: LLY, FOX, TWKS, DDOG and More
Gap Ups
1. $ノボ・ノルディスク(NVO.US)$ - up 13.4%
2. $イーライリリー(LLY.US)$ - up 10.5%
3. $ジェームス・ハーディ・インダストリーズ(JHX.US)$ - up 10.1%
4. $ニューヨーク・タイムズ(NYT.US)$ - up 3.3%
5. $ポスコ・ホールディングス(PKX.US)$ - up 2.9%
6. $フォックス・コーポレーション クラスB(FOX.US)$ - up 2.8%
7. $フォックス・コーポレーション クラスA(FOXA.US)$ - up 2.8%
8. $ウエスト ファーマシューティカル サービシズ(WST.US)$ - up 2.5...
8/9 watchlist ⚡️
$アカマイ・テクノロジーズ(AKAM.US)$$ブラッシュ・オーラル・ケア(BRSH.US)$$エクストラ・スペース・ストレージ(EXR.US)$$INVOバイオサイエンス(INVO.US)$$Leju Holdings(LEJU.US)$$908デバイシズ(MASS.US)$$マルケタ(MQ.US)$$ペン・エンターテインメント(PENN.US)$$Proterra(PTRA.US)$$サラリウス・ファーマシューティカルズ(SLRX.US)$$スーパー・マイクロ・コンピューター(SMCI.US)$$タンゴ・セラピューティクス(TNGX.US)$$ソートワークス・ホールディング(TWKS.US)$$トゥイリオ(TWLO.US)$$ウィン・リゾーツ(WYNN.US)$
コラムDigital IT Services Preview | Not Out of the Woods Yet On Negative Estimate Revision Risk
The Digital IT Services group is expected to see a downside risk to its estimates, given weak demand for project-based services and possible delays in bookings ramp. Although snap-back potential to pre-pandemic growth rates is seen at some point next year, there is still caution in the group until stability in estimates is observed. Revision risk is possible, and negative revision trends have be...
good time to buy
まだコメントはありません